KalVista Plans Quick FDA Filing After Phase III Success In On-Demand HAE Therapy

 
• By Joseph Haas

The firm’s oral kallikrein inhibitor might offer a better overall profile for on-demand treatment than currently approved therapeutic and prophylactic agents, analysts said.

Rare Diseases
KalVista hopes it has the latest advance in rare disease HAE • Source: Shutterstock

More from Clinical Trials

More from R&D